Meloxicam: a review of its pharmacokinetics, efficacy and tolerability following intramuscular administration
|
|
- Piers Marshall
- 5 years ago
- Views:
Transcription
1 Inflamm. res. 50, Supplement 1 (2001) S5 S /01/01S5-05 $ /0 Birkhäuser Verlag, Basel, 2001 Inflammation Research Meloxicam: a review of its pharmacokinetics, efficacy and tolerability following intramuscular administration L. Euller-Ziegler 1, P. Velicitat 2, E. Bluhmki 3, D. Türck 3, S. Scheuerer 3 and B. Combe 4 1 Service de Rhumatologie, Hôpital de l Archet, CHU de Nice, BP 3079, Nice Cédex, France, Lziegler@unice.fr 2 Medical Department, Boehringer Ingelheim, Reims, France 3 Boehringer Ingelheim GmbH, Biberach, Germany 4 Fédération de Rhumatologie, Hôpital Lapeyronie, Montpellier, France Received 21 March 2000; returned for revision 22 March 2000; accepted 27 October 2000 Abstract. This paper reviews published studies on the intramuscular use of meloxicam in acute rheumatic conditions. Data were obtained from 68 healthy volunteers and >800 patients with conditions such as arthritis, sciatica and lumbago who were treated with intramuscular injections of meloxicam compared with oral formulations. Intramuscular meloxicam appears to have a more rapid onset of action than oral meloxicam in acute inflammatory rheumatism. Local tolerance of im meloxicam was consistently good in both volunteers and patients, with respect to creatine phosphokinase levels and local reactions. Meloxicam im was also superior to other drugs such as piroxicam with respect to local tolerance. The incidence of adverse events, including gastrointestinal events, was low. Therefore, im meloxicam is an alternative to achieve rapid relief of acute pain in patients with acute inflammatory rheumatism. However, the recurrent use of im meloxicam is not recommended and patients should be switched to the oral formulation for chronic use. Key words: Meloxicam Intramuscular Rheumatoid arthritis Non-steroidal anti-inflammatory drugs Introduction Non-steroidal anti-inflammatory drugs (NSAIDs) are extensively used to reduce inflammation and associated pain in rheumatic diseases and other disorders. During acute, painful exacerbations of rheumatoid arthritis and sciatica, rapid pain relief is required. In such cases, NSAID therapy may initially be administered intramuscularly (im) so that maximum plasma concentrations, which may equate with the onset of therapeutic effect, are achieved more rapidly than after oral administration. However, treatment with im formulations of NSAIDs should only be used for the first few days and patients should be switched to an oral formulation as soon as possible. Correspondence to: L. E. Ziegler In order to realise the therapeutic benefits of the im route, it is vital that both the systemic and local tolerability of the NSAID are good. The systemic tolerability of a NSAID is independent of the route of administration, although some patients may tolerate an im NSAID but not the same drug given orally, possibly due to psychological factors [1]. However, local tolerance of the im formulations of traditional NSAIDs is often poor, resulting in local tissue irritation and necrosis [1 3]. Meloxicam is a novel NSAID which inhibits cyclooxygenase (COX)-2 more potently than COX-1 and has been extensively evaluated in rheumatic disorders. When administered orally at a daily dose of 7.5 mg in osteoarthritis or 15 mg for chronic inflammatory rheumatism (rheumatoid arthritis or ankylosing spondylitis), meloxicam is as effective as traditional NSAIDs and is associated with superior gastrointestinal tolerability [4 7]. This article will examine the use of im meloxicam in the acute situation, particularly with respect to onset of action, and will also assess the local and overall tolerability of im meloxicam. Preclinical studies The preclinical pharmacology of meloxicam (Fig. 1) has been extensively reviewed [8, 9]. In animal models, meloxicam showed potent anti-inflammatory and anti-arthritic activity combined with a low propensity to induce stomach ulceration. Fig. 1. Structure of meloxicam.
2 S6 L. Euller-Ziegler et al. Inflamm. res., Supplement 1 (2001) The tolerance of im meloxicam at the injection site was investigated in two studies in Chbb:HM rabbits [10]. The first study compared a single im injection of either placebo solution, saline solution or meloxicam solution (5 mg in 0.5 ml). The second study compared meloxicam with piroxicam and diclofenac administered as a single im injection. The test drugs were injected according to their relative volume ratio in humans (meloxicam 0.5 ml, piroxicam 0.33 ml, diclofenac 1 ml). Both studies showed the local tolerance of meloxicam to be very good, with only small, transient microscopic changes at the site of administration. In the first study meloxicam showed equivalent local tolerance to placebo. In the second study meloxicam demonstrated better local tolerance than im piroxicam and diclofenac as, unlike meloxicam, im administration of both piroxicam and diclofenac resulted in the development of an extensive solitary necrotic area. Pharmacokinetics of im meloxicam The pharmacokinetics of im meloxicam have been investigated in four volunteer studies. A dose-escalating study was conducted in which 32 volunteers were randomised to receive either meloxicam (5, 10, 20 or 30 mg) or placebo. Dose proportionality was demonstrated over the dose range 5 30 mg for C max and AUC. The maximum plasma concentration was reached within 1.5 h of administration and 90% of the C max was achieved within min for all four doses of meloxicam [11]. In comparison, C max was not attained until 5 6 h after the administration of oral meloxicam [12]. A two-way cross-over randomised, open study (Boehringer Ingelheim, data on file, study ) directly compared the pharmacokinetics of a single 15 mg im dose of meloxicam with a single 15 mg oral dose in 12 healthy subjects. Results showed C max values were reached at approximately 1.5 h after im injection and at about 6 h after oral administration (Fig. 2). Twelve volunteers received single doses of meloxicam (15 mg) im and intravenously (iv) in a two-way cross-over design study, with a 2-week washout period between doses (Boehringer Ingelheim, data on file, study ). Meloxicam was rapidly and completely absorbed following im administration; C max was reached within 1.5 h and absolute bioavailability was 102% [11]. The elimination half-life was comparable between im and iv administration (16.2 h vs Fig. 2. Plasma concentration/time curve for 15 mg meloxicam im versus 15 mg meloxicam tablets in 12 healthy volunteers h, respectively) [11]. Plasma clearance was also similar, irrespective of route of administration, at 7 9 ml/min. Table 1 compares the mean pharmacokinetic parameters for meloxicam im, iv and oral formulations. The complete absorption of meloxicam was confirmed (absolute bioavailability 97%) in a similar study of meloxicam 7.5 mg involving 12 healthy volunteers (Boehringer Ingelheim, data on file, study ). C max (0.99 mg/l) was reached within approximately 1 h and the mean elimination half-life was 18 h, consistent with results observed with im meloxicam 15 mg [11]. Efficacy of intramuscular meloxicam The clinical efficacy of im and oral meloxicam have been compared in two studies in patients with acute sciatica [13] and rheumatoid arthritis [14]. Both trials used a doubledummy design in order to ensure the trial was double blinded. This design also reduced the potential psychological injection effect [1] which may influence the efficacy of im agents. The onset and intensity of action of im and oral meloxicam (15 mg) were compared in patients with acute sciatica [13]. Global efficacy assessments demonstrated that both im and oral meloxicam (15 mg) were effective in relieving pain in patients with acute sciatica. The mean time to onset of analgesic action was not significantly different between patients receiving im and oral meloxicam (mean 80 min vs 89 min, respectively). Furthermore, both im and oral meloxicam (15 mg) significantly reduced spontaneous pain compared with baseline, although no significant difference was Table 1. Comparison of the mean pharmacokinetics parameters after single im, iv and oral administration. Route of Meloxicam C max t max t 1/2 AUC 0 CL/f MRT V z /f administration dose (mg) (mg/l) (h) (h) (mg.h/l) (ml/min) (h) (l) iv (infusion) iv (bolus) im Oral (capsule) [9, 11, 12].
3 Inflamm. res., Supplement 1 (2001) Intramuscular administration of meloxicam S7 Fig. 3. Time to maximum improvement (degree of elevation in the straight-leg-raising test) in induced pain after treatment with im or oral meloxicam 15 mg in patients with acute sciatica. Adapted from Auvinet et al., 1995 [13], with kind permission of Excerpta Medica Inc. observed for this parameter between the two treatment groups. However, im meloxicam significantly reduced the time to maximum improvement in induced pain (as assessed by the straight-leg-raising test) compared with oral meloxicam (p < 0.01) (Fig. 3), a measure which is clinically more meaningful than spontaneous pain [13]. This occurred during the first hour in 43.5% of patients treated with the im formulation compared with 15.1% of patients given oral meloxicam (p = 0.002) [13]. Oral and im formulations of meloxicam were also both effective in the treatment of acute exacerbations of rheumatoid arthritis [14]. Significant improvements in overall pain and disease activity were observed for both formulations, with no significant difference in terms of whether the patients received im or oral meloxicam. Intramuscular meloxicam was significantly better than oral meloxicam with respect to time to onset of action (p = 0.012) (Fig. 4), as well as global efficacy assessed by patient (p = 0.03) and the duration of morning stiffness (p = 0.026) [14]. Fig. 5. Global efficacy (good and satisfactory) as assessed on a 4-point verbal rating sale by the clinician in patients with rheumatoid arthritis and osteoarthritis receiving im meloxicam (15 mg) or piroxicam (20 mg). Adapted from Ghozlan et al., 1996 [16], with kind permission of Oxford University Press. The comparative efficacy of a single dose of im meloxicam and piroxicam has been evaluated in two studies [15, 16]. Bosch et al. [15] investigated the efficacy of im meloxicam (15 mg), followed by 7 days of oral meloxicam (15 mg/ day) compared with an im dose of piroxicam (20 mg) followed by 7 days of oral piroxicam (20 mg/day) in 169 patients with acute lumbago. The median time to onset of pain relief was comparable in the meloxicam and piroxicam groups (45 and 40 min, respectively) following im injection [15]. Improvement in pain was rapid in both groups with severe or very severe pain being reported by only 6% of meloxicam-treated patients and 10% of patients receiving piroxicam 90 min after the injection. A comparative study involving 210 patients with osteoarthritis or rheumatoid arthritis was conducted to compare im meloxicam (15 mg) with im (20 mg) [16]. Assessment of global efficacy by the investigator showed a significant advantage for im meloxicam over im piroxicam in patients with rheumatoid arthritis (Fig. 5). In addition, the overall pain intensity was significantly improved in patients with osteoarthritis receiving meloxicam in comparison to those receiving piroxicam (p = 0.02). Tolerability of intramuscular meloxicam Fig. 4. Survival distribution curve for im and oral meloxicam regarding onset of analgesic action within the first 6 h in patients with rheumatoid arthritis. Adapted with kind permission from Combe et al, this supplement. Creatine phosphokinase (CPK) levels are widely used as an indicator of local tissue damage after im injections [2, 17]. No rise in CPK (or the CPK isoenzyme selective for skeletal muscle) levels was detected after im injections of meloxicam (5, 10, 15, 20 and 30 mg) in any of the volunteer studies [11] or the clinical studies [13 16, 18]. Figure 6 shows the maximum changes in CPK-MM compared with baseline during volunteer studies.
4 S8 L. Euller-Ziegler et al. Inflamm. res., Supplement 1 (2001) In two comparative studies with im piroxicam (20 mg), the overall tolerability of im meloxicam (15 mg) [as assessed by clinician and patient] was rated as very good by the majority of patients in both groups [15, 16]. There were no significant differences between the groups in relation to the incidence of adverse events in either study. Furthermore, the incidence of gastrointestinal adverse events were low for both groups in both studies, with no significant differences between the groups [15, 16]. Discussion and conclusions Fig. 6. Maximum changes to baseline of CPK-MM in the time range > 0 to 24 h for meloxicam im at different dose levels. [Data on file, study ]. In contrast, in a comparative study of im meloxicam versus im piroxicam, CPK levels showed a significant increase from baseline to 59% in the piroxicam group (p = 0.01), but there was no mean change in CPK levels in the meloxicam group [16]. Furthermore, CPK levels increased from baseline by > 30 IU/l in 22.6% of the piroxicam group compared with only 3.8% of the meloxicam group (p = ). Local tolerability of im meloxicam in both volunteer and clinical studies has been good, confirming the CPK findings [11, 13 16, 18]. In the comparative studies against oral meloxicam, which had double-dummy designs, local tolerability ratings for im meloxicam were similar to those for im placebo [13, 18]. Furthermore, in a comparative study against piroxicam, im meloxicam was associated with significantly less local reddening (p = 0.03) and improved global local tolerability as assessed both by the physician (p = 0.045) and the patient (p = 0.029) [16] (Fig. 7). Fig. 7. Clinician s assessment of local tolerability after the first injection of meloxicam or piroxicam. Adapted with kind permission from Ghozlan et al., 1996 [16], with kind permission of Excerpta Medica Inc. Intramuscular injections of NSAIDs are usually used for the short-term treatment of acute pain as they generally provide a more rapid onset of action. However, the im route has no further advantages over oral administration it is not more efficacious or better tolerated. Therefore there is usually no medical rationale to extend the use of the im formulation beyond the very first days of treatment. Several clinical studies have demonstrated that, even after allowing for the psychological advantages of the im route, im meloxicam has a more rapid onset of action than oral meloxicam in acute inflammatory rheumatism. This is specifically noted in efficacy endpoints such as time to maximum improvement in induced pain, which is considered to be clinically more meaningful than spontaneous pain [13]. This confirms the theoretical pharmacokinetic advantages of using the im route for initiation of treatment. CPK is an indicator of muscle fibre damage; therefore changes in CPK levels are an important factor in the evaluation of local tolerability. Intramuscular injections traditionally result in elevated CPK levels, which may be due to several factors such as chemotoxicity, stimulation of histamine release and direct muscle trauma [2]. There are reports of marked increases in CPK levels after im administration of several of the classical NSAIDs [3, 16]. Mean increases in CPK from baseline of 147% with piroxicam and 922% with diclofenac have been reported in previous trials [3]. However, local tolerance of im meloxicam has been consistently good in both volunteers and patients, both with respect to CPK levels and local reactions. This confirms the results of animal studies where rabbits treated with im diclofenac and piroxicam developed necrotic areas in their muscles but no necrotic areas were seen in rabbits treated with im meloxicam [10]. Clinical comparator studies with im piroxicam have also shown im meloxicam to have superior local tolerance. CPK levels increased in the piroxicam group while they were stable in the meloxicam group, and meloxicam was associated with significantly less local reddening and improved global local tolerability. This finding reflects earlier studies on local reactions to im NSAIDs where, although clinically superior to that of im diclofenac, im piroxicam exhibited unacceptable local reactions with injections causing burning, pain, redness and induration [2, 3]. Overall, the tolerability of im meloxicam was very good in the majority of patients with rheumatic diseases and the incidence of adverse events, including gastrointestinal events, were low. This tolerability profile was comparable with im piroxicam and is typical of the superior tolerability profile exhibited by NSAIDs which are less toxic and better
5 Inflamm. res., Supplement 1 (2001) Intramuscular administration of meloxicam S9 tolerated than traditional analgesic/anti-inflammatory agents such as aspirin. In conclusion, in patients with acute inflammatory rheumatism, meloxicam may be given im as an alternative to the oral route in order to achieve rapid pain relief, with excellent local and systemic tolerability comparable with oral formulations of meloxicam. However, there is no medical rationale to extend the use of im formulation beyond the very first days of treatment for the acute flare, and patients should be switched to the oral formulation as soon as possible. References [1] Avouac B. Intramuscular use of NSAIDs. In: Famely JP, Paulus HE (eds). Therapeutic applications of NSAIDs. New York: Marcel Dekker 1992; [2] Cacace L. Elevated serum CPK after drug injections. N Engl J Med 1972; 287: [3] Vaccarino V, Sirtoni R, Bufalino L. Local and systemic tolerability of piroxicam after intramuscular administration in healthy volunteers. Curr Ther Res 1989; 45: [4] Barner A. Review of clinical trials and benefit/risk ratio of meloxicam. Scand J Rheumatol 1996; 25 (Suppl 102): [5] Distel M, Mueller C, Bluhmki E, Fries J. Safety of meloxicam: a global analysis of clinical trials. Br J Rheumatol 1996; 35 (Suppl 1): [6] Dequeker J, Hawkey C, Kahan A, Steinbrück K, Alegre C, Baumelou E, et al. On behalf of the SELECT Study Group. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large Scale Evaluation of COX inhibiting Therapies (SELECT) trial in osteoarthritis. Br J Rheumatol 1998; 37: [7] Hawkey C, Kahan A, Steinbrück K, Alegre C, Baumelou E, Begaud B, et al. and the international MELISSA Study Group. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. Br J Rheumatol 1998; 37: [8] Engelhardt G. Pharmacology of meloxicam, a new non-steroidal anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2. Br J Rheumatol 1996; 35 (Suppl 1): [9] Degner F, Türck D, Pairet M. Pharmacological, pharmacokinetic and clinical profile of meloxicam. Drugs of Today 1998; 34 (Suppl A): [10] Stei P, Kruss B, Wiegleb J, Trach V. Local tissue tolerability of meloxicam, a new NSAID: indications for parenteral, dermal and mucosal administration. Br J Rheumatol 1996; 35 (Suppl 1): [11] Narjes H, Türck D, Busch U, Heinzel G, Nehmiz G. Pharmacokinetics and tolerability of meloxicam after im administration. Br J Clin Pharmacol 1996; 41: [12] Türck D, Roth W, Busch U. A review of the clinical pharmacokinetics of meloxicam. Br J Rheumatol 1996; 35 (Suppl 1): [13] Auvinet B, Ziller R, Appelboom T, Velicitat P. Comparison of the onset and intensity of action of intramuscular meloxicam and oral meloxicam in patients with acute sciatica. Clin Ther 1995; 17: [14] Combe B, Velicitat P, Garzon N, Koneke N, Bluhmki E. Comparison of intramuscular and oral meloxicam in rheumatoid arthritis patients. [This supplement]. [15] Bosch H-C, Sigmund R, Hettich M. Efficacy and tolerability of intramuscular and oral meloxicam in patients with acute lumbago: a comparison with intramuscular and oral piroxicam. Curr Med Res Opin 1997; 14: [16] Ghozlan POR, Bernhardt M, Velicitat P, Bluhmki E. Tolerability of multiple administration of intramuscular meloxicam: a comparison with intramuscular piroxicam in patients with rheumatoid arthritis and osteoarthritis. Br J Rheumatol 1996; 35 (Suppl 1): [17] Steiness E, Rasmussen F, Svendsen O, Nielsen P. A comparative study of serum creatine phosphokinase (CPK) activity in rabbits, pigs and humans after intramuscular injection of local damaging drugs. Acta Pharmacol Toxicol 1978; 42: [18] Baturone M, Euller-Ziegler L, Kneer W, Bluhmki E, Morene J. The intramuscular formulation of the COX-2 inhibitor meloxicam is effective and safe in osteoarthritis. Presented at 3rd APLAR congress, The Philippines, January 1998.
Pharmacokinetics and tolerability of meloxicam after i.m. administration
Br J Clin Pharmacol 1996; 41: 135-139 Pharmacokinetics and tolerability of meloxicam after i.m. administration H. NARJES, D. TURCK, U. BUSCH, G. HEINZEL & G. NEHMIZ Human Pharmacology Centre and Department
More informationMeloxicam vs etodolac cox 2 inhibition
Meloxicam vs etodolac cox 2 inhibition The Borg System is 100 % Meloxicam vs etodolac cox 2 inhibition of GI. Aspirin inhibits plt aggregration via inhibition of platelet COX. Meloxicam least. Etodolac
More informationMetacam 1.5 mg/ml oral suspension for dogs
Metacam 1.5 mg/ml oral suspension for dogs Species:Dogs Therapeutic indication:pharmaceuticals: Neurological preparations: Analgesics, Other NSAIDs, Locomotor (including navicular and osteoarthritis) Active
More informationJust where it s needed.
Relief. Just where it s needed. Tissue-selective 7,8 Strong safety profile 5,6,10,11 For dogs and cats Onsior is available in a range of convenient and easy-to-dose formulations. Injectable solution for
More informationBIOEQUIVALENCE STUDY OF TWO BRANDS OF MELOXICAM TABLETS IN HEALTHY HUMAN PAKISTANI MALE SUBJECTS
Acta Poloniae Pharmaceutica ñ Drug Research, Vol. 68 No. 1 pp. 115ñ119, 2011 ISSN 0001-6837 Polish Pharmaceutical Society BIOEQUIVALENCE STUDY OF TWO BRANDS OF MELOXICAM TABLETS IN HEALTHY HUMAN PAKISTANI
More informationEPAR type II variation for Metacam
23 June 2011 EMA/674662/2011 International Non-proprietary Name: Meloxicam Procedure No. EMEA/V/C/033/II/084 EU/2/97/004/026, 33-34 Scope: Type II Addition of indication for cats Page 1/6 Table of contents
More informationAbstract. Introduction. reduce pain to tolerable level for the patient with minimal side effects. [3]
An appraisal of innovative meloxicam mucoadhesive films for periodontal postsurgical pain control: A double blinded, randomized clinical trial of effectiveness S. Raja Rajeswari, Triveni M. Gowda, Tarun
More informationCaution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
BOEHRINGER INGELHEIM VETMEDICA, INC. USA Product Label http://www.vetdepot.com 2621 NORTH BELT HIGHWAY, ST. JOSEPH, MO, 64506 2002 Telephone: 800 325 9167 Fax: 816 236 2717 Email: www.bi vetmedica.com
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Melosolute 5 mg/ml solution for injection for cattle, pigs, dogs and cats. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One ml
More informationScientific discussion
21 February 2011 EMA/CVMP/510016/2010 Veterinary Medicines and Product Data Management This module reflects the initial scientific discussion for the approval of Melosus (as published in February 2011).
More informationSUMMARY OF PRODUCT CHARACTERISTICS. 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Emdocam 20 mg/ml solution for injection for cattle, pigs and horses
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Emdocam 20 mg/ml solution for injection for cattle, pigs and horses 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains:
More informationNon-steroidal anti-inflammatory drugs (NSAIDs) are used widely to relieve pain, with or without
May 2013 Contents About NSAIDs What about COXselectivity? How effective are NSAIDs? Adverse effects of NSAIDs How frequent are the adverse effects of NSAIDs? General prescribing guidelines for NSAIDs What
More informationFinal Report. Project code: P.PSH.0653 Prepared by: Fiona Cotter Troy Laboratories Pty Ltd Date published: July 2014
Final Report Project code: P.PSH.0653 Prepared by: Fiona Cotter Troy Laboratories Pty Ltd Date published: July 2014 PUBLISHED BY Meat & Livestock Australia Limited Locked Bag 991 NORTH SYDNEY NSW 2059
More informationStart of new generation of NSAIDs?
Vet Times The website for the veterinary profession https://www.vettimes.co.uk Start of new generation of NSAIDs? Author : Peter Lees Categories : Vets Date : May 16, 2011 Peter Lees discusses development
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Melosolute 20 mg/ml solution for injection for cattle, pigs and horses. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains:
More informationMeloxicam withdrawal time veterinarian bovine
Meloxicam withdrawal time veterinarian bovine The Borg System is 100 % Meloxicam withdrawal time veterinarian bovine Meloxicam Pain Relief in Cows and Calves. Meloxicam meat and milk withdrawal the standard
More informationThe new meloxicam range for cattle, pigs & horses
The new meloxicam range for cattle, pigs & horses Melovem 5 mg/ml Melovem 20 mg/ml Melovem 30 mg/ml The new Melovem range + Many indications for cattle, horses and pigs + Accurate dosing Dopharma has obtained
More informationMetacam. The Only NSAID Approved for Cats in the US. John G. Pantalo, VMD Professional Services Veterinarian. Think easy. Think cat. Think METACAM.
Metacam The Only NSAID Approved for Cats in the US John G. Pantalo, VMD Professional Services Veterinarian Think easy. Think cat. Think METACAM. Today s Agenda New pain management guidelines for cats Only
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Zubrin 50 mg oral lyophilisates for dogs Zubrin 100 mg oral lyophilisates for dogs Zubrin 200 mg oral lyophilisates
More informationMetacam is an anti-inflammatory medicine used in cattle, pigs, horses, dogs, cats and guinea pigs.
EMA/CVMP/259397/2006 EMEA/V/C/000033 An overview of Metacam and why it is authorised in the EU What is Metacam and what is it used for? Metacam is an anti-inflammatory medicine used in cattle, pigs, horses,
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Novem 5 mg/ml solution for injection for cattle and pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains:
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Metacam 5 mg/ml solution for injection for cattle and pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains:
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Metacam 5 mg/ml solution for injection for cattle and pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains:
More informationDon t let arthritis slow down your dog!
Don t let arthritis slow down your dog! abcd DOG CAT ACUTE CHRONIC PERIOPERATIVE INJECTABLE ORAL SUSPENSION CHEWABLE Keeping your dog in the prime of life Is your dog at risk of developing arthritis? As
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Loxicom 0.5 mg/ml oral suspension for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Rifen 100 mg/ml solution for injection for horses, cattle and swine. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains:
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Animeloxan 1.5 mg/ml oral suspension for dogs. Active substance: Meloxicam 1.5 mg (equivalent to 0.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Animeloxan 1.5 mg/ml oral suspension for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of suspension contains:
More informationScientific Discussion post-authorisation update for Rheumocam extension X/007
5 May 2011 EMA/170257/2011 Veterinary Medicines and Product Data Management Scientific Discussion post-authorisation update for Rheumocam extension X/007 Scope of extension: addition of 20 mg/ml solution
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/127
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/127 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Metacam 5 mg/ml solution for injection for cattle and pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml
More informationDISPOSITION STUDY OF MELOXICAM ALONE AND ALONG WITH ENROFLOXACIN IN MALE BUFFALO CALVES AFTER INTRAVENOUS ROUTE
Wayamba Journal of Animal Science ISSN: 2012-578X; P322 - P326, 2012 First Submitted May 04, 2012; Number 1337248676 DISPOSITION STUDY OF MELOXICAM ALONE AND ALONG WITH ENROFLOXACIN IN MALE BUFFALO CALVES
More informationNSAIDs Are You Following the Rules?
NSAIDs Are You Following the Rules? As equestrians, we expect a lot from our performance horses. Sometimes pain and inflammation of their joints can happen right before a show or competition. Before administering
More informationNSAIDs: the Past, Present, and Future
NSAIDs: the Past, Present, and Future Resident Seminar - November 2017 Lisanne Gallant, DVM Large Animal Medicine Resident Outline Physiology Review Use in Large Animals Adverse Effects Cases The Future
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT AT, BE, BG, CY, CZ, DE, EE, EL, ES, FR, HR, HU, IE, IT, LT, LU, NL, PT, RO, SK, UK: Kelaprofen 100 mg/ml, solution for injection
More informationProviding Constant Analgesia with OROS Ò Hydromorphone
Vol. 33 No. 2S February 2007 Journal of Pain and Symptom Management S19 Advances in the Long-Term Management of Chronic Pain: Recent Evidence with OROS Ò Hydromorphone, a Novel, Once-Daily, Long-Acting
More informationCommonly Used Analgesics
Commonly Used Analgesics The following analgesics are intended for general use in the species of laboratory animals commonly used at NEOUCOM. The animals genetic background and other factors may have a
More informationOptimizing Pain Control A Critical Understanding of NSAIDs
Optimizing Pain Control A Critical Understanding of NSAIDs James S. Gaynor, DVM, MS, DACVA, DAAPM Colorado Springs, CO USA 719-266-6400 800-791-2578 www.peakvets.com Principles of Acute & Chronic Pain
More informationIrish Greyhound Board. Scientific Advisory Committee on Doping and Medication Control. Opinion on Carprofen
Irish Greyhound Board Scientific Advisory Committee on Doping and Medication Control Opinion on Carprofen The Committee has been examining the advice it would give the Board on the threshold for carprofen
More informationISMP Canada HYDROmorphone Knowledge Assessment Survey
ISMP Canada HYDROmorphone Knowledge Assessment Survey Knowledge Assessment Questions 1. In an equipotent dose, HYDROmorphone is more potent than morphine. True False Unsure 2. HYDROmorphone can be given
More informationN.C. A and T List of Approved Analgesics 1 of 5
1 of 5 Note to user: This list of commonly used analgesics and sedatives is not all-inclusive. The absence of an agent does not necessarily mean it is unacceptable. For any questions, call the Clinical
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/33
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/33 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Acticam 1.5 mg/ml oral suspension for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of Acticam 1.5
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Onsior 6 mg tablets for cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active substance:
More informationOnly for Intravenous Use in Beef and Dairy Cattle. Not for Use in Dry Dairy Cows and Veal Calves. For Intravenous or Intramuscular Use in Horses.
INTERVET INC., MERCK ANIMAL HEALTH USA Product Label http://www.vetdepot.com 556 MORRIS AVE., SUMMIT, NJ, 07901 Telephone: 862-245-4321 Order Desk: 800-648-2118 Fax: 862-245-4935 Customer Service: 800-521-5767
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT
SUMMARY OF PRODUCT CHARACTERISTICS Revised: December 2013 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Flunixin 50 mg/ml Solution for Injection for Cattle, Horses and Pigs (United Kingdom, Germany, Iceland)
More informationINTRODUCTION TO WILDLIFE PHARMACOLOGY. Lisa Fosco Wildlife Rehabilitation Manager Toronto Wildlife Centre
INTRODUCTION TO WILDLIFE PHARMACOLOGY Lisa Fosco Wildlife Rehabilitation Manager Toronto Wildlife Centre General Pharmacology Factors That Affect Drug Absorption The dosage form Blood supply to the area
More informationAustralian and New Zealand College of Veterinary Scientists. Membership Examination June Veterinary Pharmacology Paper 1
Australian and New Zealand College of Veterinary Scientists Membership Examination June 2012 Veterinary Pharmacology Paper 1 Perusal time: Fifteen (15) minutes Time allowed: Two (2) hours after perusal
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Rheumocam 1.5 mg/ml oral suspension for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains: Active
More informationAcute Laminitis in the UK The Redwings Study
Acute Laminitis in the UK The Redwings Study Nicola Jarvis BVetMed Cert AVP(EM) MRCVS Redwings Horse Sanctuary Nine farms Over 1,300 resident horses, ponies, donkeys and mules Over 500 more in guardian
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Rheumocam 1.5 mg/ml oral suspension for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains: Active
More informationPOST-OPERATIVE ANALGESIA AND FORMULARIES
POST-OPERATIVE ANALGESIA AND FORMULARIES An integral component of any animal protocol is the prevention or alleviation of pain or distress, such as that associated with surgical and other procedures. Pain
More informationWelcome to. Who Wants to be a Millionaire 50:50
0:0 Welcome to Who Wants to be a Millionaire 0 $ Million $,000 $,000 $00 0 $ Million $,000 $,000 $00 What is the generic name for the drug in Ketofen? C:Ketoprofen 0:0 0 $ Million $,000 $,000 $00 A: Ketarian
More informationAdverse Effects of Anti-Inflammatory Drugs:
Non-Steroidal anti-inflammatory drug (NSAIDs) are widely used to provide effective anti-inflammatory and analgesic therapy for patients with arthritis. However, they are associated with a high incidence
More informationSummary from the Journal of Preventive Veterinary Medicine 126 (2016) 48-53
is not approved for the indication investigated in the study. The specifications in this document shall only be used as scientific information about research activities. Summary from the Journal of Preventive
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT NEFOTEK 100 mg/ml solution for injection for cattle, horses and pigs [AT, CZ, IE, PL, SK, UK, DE, FR, ES, HU, IT, SI] COXOFEN
More informationsingle intravenous and oral doses and after 14 repeated oral
Br. J. clin. Pharmac. (1986), 22, 21-25 The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily J. K. FAULKNER
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Rycarfa 100 mg tablets for dogs (BE, DE, ES, FR, IE, IT, NL, PT, UK) Rycarfa vet 100 mg tablets for dogs (DK, FI) Carprox
More informationNSAID Toxicity in Dogs & Cats Beware of Ibuprofen!
NSAID Toxicity in Dogs & Cats Beware of Ibuprofen! One of the most common drug toxicities in companion animal medicine is accidental ingestion of over-the-counter non-steroid anti-inflammatory (NSAID)
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Carprodyl Quadri 120 mg chewable tablets for dogs Carprodyl vet. 120 mg chewable tablets for dogs (FI, SE, DK) 2. QUALITATIVE
More informationVeterinary Medicinal Product
Veterinary Medicinal Product Carprodyl Quadri 120 mg chewable tablets for dogs PART I B Pharmaceutical Form Chewable tablet Veterinary Medicinal Product Carprodyl Quadri 120mg chewable tablets for dogs
More informationCritical appraisal Randomised controlled trial questions
Critical appraisal Randomised controlled trial questions Moreau et al. (2003) Clinical evaluation of a nutraceutical, carprofen and meloxicam for the treatment of dogs with osteoarthritis Introduction
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology EMEA/MRL/728/00-FINAL April 2000 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS STREPTOMYCIN AND
More informationIs Robenacoxib Superior to Meloxicam in Improving Patient Comfort in Dog Diagnosed With a Degenerative Joint Process?
Is Robenacoxib Superior to Meloxicam in Improving Patient Comfort in Dog Diagnosed With a Degenerative Joint Process? A Knowledge Summary by Adam Swallow BVSc MRCVS 1* 1 University of Bristol * Corresponding
More informationPeriod of study: 12 Nov 2002 to 08 Apr 2004 (first subject s first visit to last subject s last visit)
Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency of Bayer's
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Inflacam 1.5 mg/ml oral suspension for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains: Active
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Meloxidyl 1.5 mg/ml oral suspension for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Composition for 1 ml Active
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT GALLIPRANT 20 mg tablets for dogs GALLIPRANT 60 mg tablets for dogs GALLIPRANT 100 mg tablets for dogs 2. QUALITATIVE
More informationDose-Dependent Inhibition of Platelet Cyclooxygenase-1 and Monocyte Cyclooxygenase-2 by Meloxicam in Healthy Subjects 1
0022-3565/99/2901-0276$03.00/0 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 290, No. 1 Copyright 1999 by The American Society for Pharmacology and Experimental Therapeutics Printed in
More informationMARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS
MARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT MARBOCYL 10%, solution for injection for cattle and swine 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Marbofloxacin...100.0
More informationWhat Veterinarians Should Tell Clients About Pain Control and Their Pets
What Veterinarians Should Tell Clients About Pain Control and Their Pets by Michele Sharkey, DVM, MS, Office of New Animal Drug Evaluation; Margarita Brown, DVM MS, Office of Surveillance and Compliance;
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE
European Medicines Agency Veterinary Medicines and Inspections EMEA/CVMP/211249/2005-FINAL July 2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE DIHYDROSTREPTOMYCIN (Extrapolation to all ruminants)
More informationThe pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens
The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens Cellular and Molecular Pharmacology Unit Catholic University of Louvain, Brussels,
More informationWithdrawal period: 93 days Milk: Not authorised for use in animals producing milk for human consumption.
A. LABELLING PARTICULARS TO APPEAR ON THE OUTER PACKAGE AND THE IMMEDIATE PACKAGE CARTON BOX AND LABELS OF 100 ml and 250 ml 1. NAME OF THE VETERINARY MEDICINAL PRODUCT TILKOMAY 300 mg/ml + 90 mg/ml solution
More informationPrescription Label. Patient Name: Species: Drug Name & Strength: Directions (amount to give how often & for how long):
Prescription Label Patient Name: Species: Drug Name & Strength: Directions (amount to give how often & for how long): Prescribing Veterinarian's Name & Contact Information: Refills: [Content to be provided
More informationProcedure # IBT IACUC Approval: December 11, 2017
IACUC Procedure: Anesthetics and Analgesics Procedure # IBT-222.04 IACUC Approval: December 11, 2017 Purpose: The purpose is to define the anesthetics and analgesics that may be used in mice and rats.
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Meloxidyl 1.5 mg/ml oral suspension for dogs. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Composition for 1 ml Active
More information- Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.
MERIAL LTD. USA Product Label http://www.vetdepot.com 3239 SATELLITE BLVD., DULUTH, GA, 30096 Telephone: 888-637-4251 Website: www.merial.com GASTROGARD Merial (omeprazole) Oral Paste for Equine Ulcers
More informationUSA Product Label LINCOCIN. brand of lincomycin hydrochloride tablets. brand of lincomycin hydrochloride injection, USP. For Use in Animals Only
USA Product Label http://www.vetdepot.com PHARMACIA & UPJOHN COMPANY Division of Pfizer Inc. Distributed by PFIZER INC. 235 E. 42ND ST., NEW YORK, NY, 10017 Telephone: 269-833-4000 Fax: 616-833-4077 Customer
More informationIrish Medicines Board
IRISH MEDICINES BOARD ACT 1995 EUROPEAN COMMUNITIES (ANIMAL REMEDIES) (No. 2) REGULATIONS 2007 (S.I. No. 786 of 2007) VPA:10778/003/002 Case No: 7003735 The Irish Medicines Board in exercise of the powers
More information[09/2018] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
[09/2018] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cronyxin 50 mg/g Oral paste for horses (DE, AT, BE, EE, LV, LT, ES, FR, IE, IT, NL, PL, UK) Cronyxin vet
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Inflacam 1.5 mg/ml oral suspension for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains: Active
More informationETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections
ETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections Robin Isaacs Chief Medical Officer, Entasis Therapeutics Dr. Isaacs is a full-time employee of Entasis Therapeutics.
More informationTreating Rosacea in the Era of Bacterial Resistance. This presentation is sponsored by Galderma Laboratories, L.P.
Treating Rosacea in the Era of Bacterial Resistance This presentation is sponsored by Galderma Laboratories, L.P. Lecture Discuss rosacea as an inflammatory condition Assess the psychosocial impact of
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Linco-Sol 400 mg/g powder for use in drinking water for pigs and chickens 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active
More informationSUMMARY OF PRODUCT CHARACTERISTICS. KELAPRIL 2.5 mg, film coated tablets for dogs and cats [FR] KELAPRIL 2,5 film coated tablets for dogs and cats
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT KELAPRIL 2.5 mg, film coated tablets for dogs and cats [FR] KELAPRIL 2,5 film coated tablets for dogs and cats 2. QUALITATIVE
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products EMEA/MRL/571/99-FINAL February 1999 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS MELOXICAM SUMMARY REPORT (2) 1. Meloxicam (4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-
More informationCHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY
CHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Antibiotics One of the most commonly used group of drugs In USA 23
More informationThe world s first and only pour-on anti-inflammatory for cattle FAST PAIN RELIEF
The world s first and only pour-on anti-inflammatory for cattle FAST PAIN RELIEF NOTHING IS SIMPLER THAN POUR-ON RELIEF FOR PAIN, FEVER AND ACUTE INFLAMMATION easy to dose easy to apply easy on animals
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Marbocare 20 mg/ml solution for injection for cattle and pigs (UK, IE, FR) Odimar 20 mg/ml solution for injection for cattle
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT DINALGEN 60 mg/ml solution for injection for pigs (all countries except FI and SE) DINALGEN VET 60 mg/ml solution for injection
More informationT u l a n e U n i v e r s i t y I A C U C Guidelines for Rodent & Rabbit Anesthesia, Analgesia and Tranquilization & Euthanasia Methods
T u l a n e U n i v e r s i t y I A C U C Guidelines for Rodent & Rabbit Anesthesia, Analgesia and Tranquilization & Euthanasia Methods Abbreviations: General Considerations IV = intravenous SC = subcutaneous
More informationPharmacokinetics of the Bovine Formulation of Enrofloxacin (Baytril 100) in Horses
C. Boeckh, C. Buchanan, A. Boeckh, S. Wilkie, C. Davis, T. Buchanan, and D. Boothe Pharmacokinetics of the Bovine Formulation of Enrofloxacin (Baytril 100) in Horses Christine Boeckh, DVM, MS a Charles
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Acecare 2mg/ml Solution for Injection for Dogs and Cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml of solution contains
More informationNon-steroidal anti-inflammatory drugs in dogs and cats what s new?
continuing education Nonsteroidal antiinflammatory drugs in dogs and cats what s new? Isabelle Iff Dr.med.vet. DipECVAA CertVetAc (IVAS) Veterinary Anaesthesia Services Zürcherstrasse 39 CH 8400 Winterthur
More informationdiscover the nextgeneration of flea & tick protection NEW TASTY CHEW ONE CHEW ONCE A MONTH
discover the nextgeneration of flea & tick protection KILLS FLEAS KILLS TICKS ONE CHEW ONCE A MONTH TASTY CHEW NEW Now there s a new oral treatment that offers effective flea AND tick control on dogs for
More informationPharmacokinetics of amoxycillin and clavulanic acid in
Br. J. clin. Pharmac. (1988), 26, 385-390 Pharmacokinetics of amoxycillin and clavulanic acid in haemodialysis patients following intravenous administration of Augmentin B. E. DAVIES', R. BOON2, R. HORTON2,
More informationSea Turtle Analgesics Selection - NSAIDS. Loggerhead Coquina (postoperative ketorolac)
Sea Turtle Analgesics Selection - NSAIDS Craig A. Harms, D.V.M., Ph.D, Dipl. ACZM North Carolina State University Loggerhead Coquina (postoperative ketorolac) $& Sources of Information!! Anecdote!! Expert
More informationSUMMARY OF PRODUCT CHARACTERISTICS. NUFLOR 300 mg/ml solution for injection for cattle and sheep
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT NUFLOR 300 mg/ml solution for injection for cattle and sheep 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains:
More informationSCIENTIFIC DISCUSSION
SCIENTIFIC DISCUSSION 1. SUMMARY OF THE DOSSIER The submission of the marketing authorisation application for Melovem was in accordance with Article 13(1) of Directive 2001/82/EC, as amended, which refers
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Selectan 300 mg/ml solution for injection for cattle and swine. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains:
More informationPharmacology Week 6 ANTIMICROBIAL AGENTS
Pharmacology Week 6 ANTIMICROBIAL AGENTS Mechanisms of antimicrobial action Mechanisms of antimicrobial action Bacteriostatic - Slow or stop bacterial growth, needs an immune system to finish off the microbe
More informationIrish Medicines Board
Irish Medicines Board (Reference Member State) DECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT Pestigon 50 mg Spot-On Solution for Cats Pestigon vet 50 mg
More information